Mesenchymal stem cell therapy for chronic major ischemic stroke
The STARTING-2 study found no evidence to suggest that treatment with intravenous preconditioned autologous mesenchymal stem cells (MSCs) improves 90-day modified Rankin Scale (mRS) outcomes in patients with chronic ischemic stroke.
Why this matters
The potential application of stem cell therapy for chronic stroke is of keen interest.
A previous incarnation of the STARTING-2 study (STARTING) used fetal bovine serum (FBS) to expand autologous MSCs for treatment but encountered efficacy limitations.